Concordia International Corp. Company Profile (NASDAQ:CXRX)

About Concordia International Corp.

Concordia International Corp. logoConcordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CXRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.50
  • 50 Day Moving Average: $2.31
  • 200 Day Moving Average: $4.70
  • 52-Week Range: $1.69 - $35.23
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 0.94
  • P/E Growth: 0.00
  • Market Cap: $127.54M
  • Outstanding Shares: 51,017,000
  • Beta: 0.12
Profitability:
  • Net Margins: -81.40%
  • Return on Equity: 22.81%
  • Return on Assets: 3.48%
Debt:
  • Debt-to-Equity Ratio: 10.65%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.82%
Additional Links:
Companies Related to Concordia International Corp.:

Analyst Ratings

Consensus Ratings for Concordia International Corp. (NASDAQ:CXRX) (?)
Ratings Breakdown: 6 Sell Ratings, 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 1.73)
Consensus Price Target: $28.68 (1,047.20% upside)

Analysts' Ratings History for Concordia International Corp. (NASDAQ:CXRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017TD SecuritiesDowngradeHold -> ReduceView Rating Details
12/9/2016ScotiabankDowngradeSector Perform -> Underperform$2.00 -> $0.50View Rating Details
12/7/2016RBC Capital MarketsDowngradeSector Perform -> UnderperformView Rating Details
11/7/2016Bloom BurtonDowngradeHold -> SellView Rating Details
11/7/2016Canaccord GenuityDowngradeHold -> SellView Rating Details
9/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutralView Rating Details
8/15/2016CIBCDowngradeSector Perform -> Underperform$7.80View Rating Details
8/15/2016GMP SecuritiesDowngradeBuy -> HoldView Rating Details
6/21/2016Royal Bank Of CanadaReiterated RatingOutperform$73.00View Rating Details
3/31/2016LaurentianReiterated RatingBuy$60.00 -> $55.00View Rating Details
3/28/2016Laurentian Bank of CanadaLower Price TargetBuy$60.00 -> $55.00View Rating Details
3/21/2016Dundee SecuritiesLower Price Target$46.50 -> $45.00View Rating Details
12/4/2015MackieReiterated RatingHoldView Rating Details
10/16/2015S&P Equity ResearchReiterated RatingBuy$60.00View Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$90.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Concordia International Corp. (NASDAQ:CXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316$1.05$0.69$206.00 million$185.50 millionViewListenView Earnings Details
8/12/2016Q216$1.38$1.38$229.76 million$231.70 millionViewN/AView Earnings Details
5/13/2016Q116$1.54$1.35$231.00 million$228.50 millionViewN/AView Earnings Details
3/23/2016Q415$1.32$1.24$166.60 million$191.90 millionViewN/AView Earnings Details
11/12/2015Q315$1.43$1.46$93.11 million$94.90 millionViewN/AView Earnings Details
8/13/2015Q215$0.91$0.96$84.47 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concordia International Corp. (NASDAQ:CXRX)
Current Year EPS Consensus Estimate: $3.98 EPS
Next Year EPS Consensus Estimate: $2.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.35$1.35$1.35
Q2 20161$1.52$1.52$1.52
Q3 20161$1.62$1.62$1.62
Q4 20161$1.68$1.68$1.68
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Concordia International Corp. (NASDAQ:CXRX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/16/2016quarterly$0.081.03%7/13/20167/15/20167/29/2016
3/24/2016quarterly$0.081.13%4/13/20164/15/20164/29/2016
11/17/2015quarterly$0.080.92%1/13/20161/15/20161/29/2016
8/14/2015quarterly$0.080.39%10/13/201510/15/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Concordia International Corp. (NASDAQ:CXRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Concordia International Corp. (NASDAQ:CXRX)
DateHeadline
News IconBiotech Stocks Under Scanner -- Celldex Therapeutics, Achillion Pharma, Vertex Pharma, and Concordia (NASDAQ:CXRX)
www.medindia.net - February 17 at 8:03 AM
4-traders.com logoConcordia International : Biotech Stocks Under Scanner -- Celldex Therapeutics, Achillion Pharma, Vertex Pharma, and Concordia (NASDAQ:CXRX)
www.4-traders.com - February 17 at 8:03 AM
News IconVolatile Stock Causing a Fracas Mid-Session: Concordia ... - Aiken Advocate (NASDAQ:CXRX)
aikenadvocate.com - February 16 at 6:48 PM
News IconTwo Stocks in Concentration: Concordia International Corp ... - The Newburgh Press (NASDAQ:CXRX)
newburghpress.com - February 16 at 1:47 PM
News IconConcordia International Corp (NASDAQ:CXRX) earnings could be the catalysis for positive movement (NASDAQ:CXRX)
www.financialstrend.com - February 13 at 10:23 PM
News IconUnited States Department of Commerce, Strongly backs Biotechnology (NASDAQ:CXRX)
www.usfinancialnewstoday.com - February 8 at 5:02 PM
News IconStock Price of Concordia International Corp. (CXRX) Increases 31.77% - Highland Mirror (NASDAQ:CXRX)
www.highlandmirror.com - February 6 at 6:28 AM
News IconStock Carving Out Mid-Session Gains For Traders: Concordia International Corp. (NASDAQ:CXRX) - Wall Street Beacon (NASDAQ:CXRX)
wsbeacon.com - February 1 at 10:05 PM
finance.yahoo.com logoConcordia International Corp. Makes Final Earn Out Payment to Cinven (NASDAQ:CXRX)
finance.yahoo.com - February 1 at 5:05 PM
News IconShares in the Spotlight: Concordia International Corp. (TSX:CXR) - Gilbert Daily (NASDAQ:CXRX)
gilbertdaily.com - January 30 at 5:31 PM
News IconStock Survey: Viewing Levels for Concordia International Corp. (TSX:CXR) - Gilbert Daily (NASDAQ:CXRX)
gilbertdaily.com - January 27 at 6:08 PM
News IconWhich Direction is This Stock Headed? Update on Concordia International Corp. (NASDAQ:CXRX) - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 25 at 5:47 PM
News IconFree Cash Flow Score in Focus for Concordia International Corp. (TSX:CXR) - Gilbert Daily (NASDAQ:CXRX)
gilbertdaily.com - January 25 at 5:47 PM
News IconStock Tracker: Earnings & Estimates for Concordia Healthcare Corp (NASDAQ:CXRX) - Aiken Advocate (NASDAQ:CXRX)
aikenadvocate.com - January 21 at 4:38 PM
News IconToday's Price Action: How Analysts Feel About Concordia International Corp After Today's Huge Decline? - Fair View Times (NASDAQ:CXRX)
fairviewtimes.com - January 19 at 3:00 AM
News IconIgniting Curiosity on This Name, Investor Update on Concordia ... - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 18 at 4:57 PM
News IconA Look at this Riveting Stock: Concordia International Corp. (NASDAQ:CXRX) - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 18 at 3:33 AM
News IconCan This Stock Grab Upward Traction: Concordia International Corp. (NASDAQ:CXRX) - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 16 at 4:37 PM
finance.yahoo.com logoRedHill Biopharma Provides 2017 Semi-Annual Business Update (NASDAQ:CXRX)
finance.yahoo.com - January 12 at 5:01 PM
News IconIs There Any Upside to This Stock Under $5: Concordia International Corp. (NASDAQ:CXRX) - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 9 at 9:25 PM
News IconIs There a Spark Ahead for Concordia International Corp. (NASDAQ:CXRX) - Prospect Journal (NASDAQ:CXRX)
prospectjournal.com - January 6 at 3:23 AM
News IconStreet Highjack By Active Movers: BioScrip, Inc. (NASDAQ:BIOS), Concordia International Corp. (NASDAQ:CXRX) - Street Wise Report (press release) (blog) (NASDAQ:CXRX)
streetwisereport.com - January 5 at 6:16 AM
News IconSmall-Cap Spotlight on Concordia International Corp (NASDAQ:CXRX) - The Oracle Dispatch (NASDAQ:CXRX)
oracledispatch.com - January 4 at 4:27 AM
streetinsider.com logoConcordia International (CXRX) Enters 3-Year Co-Promotion Deal RedHill Biopharma (RDHL) for Donnatal - StreetInsider.com (NASDAQ:CXRX)
www.streetinsider.com - January 3 at 6:23 PM
capitalcube.com logoETFs with exposure to Concordia International Corp. : January 3, 2017 (NASDAQ:CXRX)
www.capitalcube.com - January 3 at 6:23 PM
seekingalpha.com logoConcordia: Executive "Retirement" Another Ominous Sign - Seeking Alpha (NASDAQ:CXRX)
seekingalpha.com - December 31 at 3:04 AM
baystreet.ca logoConcordia International (CXRX) Gains on New President (NASDAQ:CXRX)
www.baystreet.ca - December 30 at 5:02 PM
seekingalpha.com logoConcordia: Executive "Retirement" Another Ominous Sign (NASDAQ:CXRX)
seekingalpha.com - December 29 at 4:59 PM
us.rd.yahoo.com logoConcordia International Corp. Provides Business Update (NASDAQ:CXRX)
us.rd.yahoo.com - December 20 at 9:44 AM
us.rd.yahoo.com logo7:04 am Concordia announces they paid the first installment of its earn-out to Cinven relating to the previously announced acquisition of Amdipharm Mercury; payment of GBP 72 mln paid; terminates enrollment in phase 3 trial evaluating PDT w (NASDAQ:CXRX)
us.rd.yahoo.com - December 20 at 9:44 AM
capitalcube.com logoETFs with exposure to Concordia International Corp. : December 19, 2016 (NASDAQ:CXRX)
www.capitalcube.com - December 20 at 9:44 AM
capitalcube.com logoETFs with exposure to Concordia International Corp. : December 8, 2016 (NASDAQ:CXRX)
www.capitalcube.com - December 8 at 5:20 PM
seekingalpha.com logoConcordia's Ominous Silence (NASDAQ:CXRX)
seekingalpha.com - December 3 at 6:49 AM
News IconResearch Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia (NASDAQ:CXRX)
www.kait8.com - December 2 at 9:25 AM
seekingalpha.com logoCan Oberman Salvage Concordia? (NASDAQ:CXRX)
seekingalpha.com - November 29 at 5:49 PM
seekingalpha.com logoConcordia: A Ship Without A Captain (NASDAQ:CXRX)
seekingalpha.com - November 25 at 4:36 PM
benzinga.com logoConcordia Healthcare Bondholder Calls For Immediate Changes, Threatens Lawsuit (NASDAQ:CXRX)
www.benzinga.com - November 25 at 4:36 PM
News IconTrader's Radar- Concordia Healthcare Corp. (NASDAQ:CXRX) - Hot Stocks Point (NASDAQ:CXRX)
www.hotstockspoint.com - November 18 at 1:38 PM
News IconConcordia Healthcare Corp. (NASDAQ:CXRX) Touched its 52-Week Low on Nov 8, 2016 - The Newburgh Press (NASDAQ:CXRX)
newburghpress.com - November 16 at 4:36 PM
News IconFinancial Review of Concordia Healthcare Corp. (NASDAQ:CXRX) - The Newburgh Press (NASDAQ:CXRX)
newburghpress.com - November 14 at 4:44 PM
moodys.com logoConcordia International Corp. -- Moody's Downgrades Concordia's CFR to Caa1; outlook negative (NASDAQ:CXRX)
www.moodys.com - November 14 at 4:44 PM
News IconSell-side is Weighing in on Concordia Healthcare Corp (NASDAQ:CXRX) Earnings - CSZ News (NASDAQ:CXRX)
cincysportszone.com - November 11 at 3:50 PM
capitalcube.com logoETF’s with exposure to Concordia International Corp. : November 10, 2016 (NASDAQ:CXRX)
www.capitalcube.com - November 10 at 1:02 PM
News IconWhat is the Fate of Concordia International Corp. (NASDAQ:CXRX) After Earnings? (NASDAQ:CXRX)
mjbstar.com - November 9 at 1:41 PM
capitalcube.com logoConcordia International Corp. :CXRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 (NASDAQ:CXRX)
www.capitalcube.com - November 9 at 1:41 PM
News IconDrug company Concordia International shares plunge more than 30 per cent (NASDAQ:CXRX)
magseriesusa.net - November 8 at 9:57 PM
seekingalpha.com logoConcordia Healthcare's (CXRX) Q3 2016 Results - Earnings Call Transcript (NASDAQ:CXRX)
seekingalpha.com - November 8 at 9:57 PM
News IconConcordia Healthcare Corp. (CXRX) Releases Quarterly Earnings Results (NASDAQ:CXRX)
discover-usa.net - November 8 at 9:57 PM
News IconConcordia Healthcare Corp (CXRX) Releases Earnings Results, Misses Expectations By $-0.33 EPS (NASDAQ:CXRX)
www.perspectivabetica.com - November 8 at 9:57 PM
News IconConcordia Healthcare Corp. (NASDAQ:CXRX) Updated Broker Price Targets (NASDAQ:CXRX)
leglobaliste.com - November 8 at 9:57 PM

Social

What is Concordia International Corp.'s stock symbol?

Concordia International Corp. trades on the NASDAQ under the ticker symbol "CXRX."

How often does Concordia International Corp. pay dividends? What is the dividend yield for Concordia International Corp.?

Concordia International Corp. declared a quarterly dividend on Monday, May 16th. Shareholders of record on Friday, July 15th will be paid a dividend of $0.075 per share on Friday, July 29th. This represents a $0.30 dividend on an annualized basis and a dividend yield of 12.00%. The ex-dividend date is Wednesday, July 13th.

Where is Concordia International Corp.'s stock going? Where will Concordia International Corp.'s stock price be in 2017?

11 brokers have issued 12 month price objectives for Concordia International Corp.'s stock. Their forecasts range from $0.50 to $73.00. On average, they anticipate Concordia International Corp.'s stock price to reach $28.68 in the next year.

What are analysts saying about Concordia International Corp. stock?

Here are some recent quotes from research analysts about Concordia International Corp. stock:

  • According to Zacks Investment Research, "Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada. " (1/10/2017)

  • Goldman Sachs Group, Inc. (The) analysts commented, "multiple challenges, including levered balance sheets, intensifying pricing pressure and deteriorating fundamentals." The brokerage's top picks are Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) and Horizon Pharma PLC (NASDAQ: HZNP)."Our analysis reveals that much of the M&A has destroyed value, and balance sheets are now bloated — making traditional multiples insufficient to capture the full story," analyst Stephan Stewart wrote in a note.Stewart expects "limited M&A, increasing payer pressure and ongoing government focus to limit branded price aggression" and "sees branded companies with durable growth and pipelines with near-term commercial opportunities as best positioned."Related Link: Biocept Is An Emerging Leader In Liquid Biopsy; Roth Starts At BuyMeanwhile, the analyst said the generics sector faces "increased manufacturer competition, FDA's focus on reducing its backlog, and purchaser consolidation" amid continued pricing pressures. "In this context, scale, portfolio exposures and pipelines increasingly matter and we await signs of stabilization before getting more positive," Stewart highlighted.Specialty Pharma Picks And Panshttp://www.benzinga.com/analyst-ratings/analyst-color/16/06/8073266/goldman-sees-26-upside-in-jazz-pharma-shares">Stewart likes Buy-rated Jazz Pharma, as it "boasts leading organic growth, returns and balance sheet quality, with 2016 catalysts to drive shares higher."In addition, the analyst also hailed Buy-rated Horizon Pharma's emerging orphan portfolio.On the flipside, the analyst recommends investors sell Impax Laboratories Inc (NASDAQ: IPXL), as he sees "high expectations, premium valuation, increasing competition and tail risk limiting relative upside."Stewart said he would avoid companies with "sizeable exposure to the generic pain market," such as Endo International plc - Ordinary Shares (NASDAQ: ENDP) and Mallinckrodt PLC (NYSE: MNK) — both Neutral rated.Related Link: Goldman Likes Horizon Pharma's Emerging Orphan FranchiseThe analyst noted he is concerned by the durability of Neutral-rated Concordia Healthcare Corp (NASDAQ: CXRX)'s North American portfolio, on historical price reliance. "However, the company's ongoing strategic review could limit downside."The analyst also likes Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s (Neutral) "biosimilar and novel pipeline opportunities, but expect(s) litigation around its near-term generic Copaxone 40mg opportunity to drive near-term stock performance."Sector CatalystsAmong the sector catalysts, Stewart lists out the following key upcoming events:1. "Expected 1Q17 approval and trial decision on MNTA's generic Copaxone 40mg, which could more than double its current revenue base and provide a path to the more attractive longer term biosimilars and novel compound pipeline.2. "HZNP's 4Q16 phase 3 data for Actimmune in FA, which we believe could be a $500+ million opportunity if approved, versus HZNP's current revenue run rate of ~$1,000 million.3. "JAZZ's anticipated 4Q Phase 3 data for JZP-110, a wake promoting agent with a potentially large addressable market and comfortable $300+ million revenue opportunity versus JAZZ's current revenue base of $1.5 billion." (6/6/2016)

Who owns Concordia International Corp. stock?

Concordia International Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Warlander Asset Management LP (2.75%), Raging Capital Management LLC (0.79%), Public Sector Pension Investment Board (0.69%), Renaissance Technologies LLC (0.56%), Continental Advisors LLC (0.31%) and GLG Partners LP (0.25%).

Who sold Concordia International Corp. stock? Who is selling Concordia International Corp. stock?

Concordia International Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and GLG Partners LP.

Who bought Concordia International Corp. stock? Who is buying Concordia International Corp. stock?

Concordia International Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Warlander Asset Management LP, Continental Advisors LLC, Partners Group Holding AG and Allianz Asset Management AG.

How do I buy Concordia International Corp. stock?

Shares of Concordia International Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Concordia International Corp. stock cost?

One share of Concordia International Corp. stock can currently be purchased for approximately $2.50.

Concordia International Corp. (NASDAQ:CXRX) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Concordia International Corp. (NASDAQ:CXRX)

Earnings History Chart

Earnings by Quarter for Concordia International Corp. (NASDAQ:CXRX)

Dividend History Chart

Dividend Payments by Quarter for Concordia International Corp. (NASDAQ:CXRX)

Last Updated on 2/20/2017 by MarketBeat.com Staff